The company is a leading, US-based manufacturer and provider of radio isotopes for the medical and pharmaceutical market and has been in production since 2021, currently operating the only US-based six-beam cyclotron. Due to the extreme shortage of radio medical isotopes nationally and globally, the current and projected production will be absorbed into the market immediately. The company is requesting $150M for the purpose of expanding total production with the purchase of one additional 30 megavolt cyclotron, and two smaller, 18 megavolt cyclotrons allowing them to better focus on the cost-effective production of ultra-high value isotopes in current and long-term world-wide short supply. There are limited competitors for the isotopes development identified above as the barriers to entry are formidable for those attempting to join the industry and once the company completes the acquisition of the proposed additional cyclotrons, it is expected to generate a projected $1.15 billion in net cash flow over the first ten years of operation. The cyclotrons are expected to operate for 50+ years. Even with the additional cyclotrons, the need for these isotopes cannot meet world demand and the company can demonstrate all its production will be consumed.